Trial Profile

An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Asthma
Focus Pharmacodynamics; Pharmacokinetics; Registrational
Acronyms TATE
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

11 Apr 2024 Primary endpoint (PD evaluation) has been met, according to an AstraZeneca media release.
11 Apr 2024 Primary endpoint (PK evaluation; time to reach Cmax (Tmax)) has been met, according to an AstraZeneca media release.
11 Apr 2024 Primary endpoint (PK evaluation; terminal phase elimination half-life (t1/2)) has been met, according to an AstraZeneca media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com